Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?

Estey E, Karp JE, Emadi A, Othus M, Gale RP.

Leukemia. 2020 Jan 8. doi: 10.1038/s41375-019-0704-5. [Epub ahead of print] Review.

PMID:
31915366
2.

A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.

Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT.

Cancer. 2019 Dec 20. doi: 10.1002/cncr.32657. [Epub ahead of print]

PMID:
31860140
3.

Conception, Implementation, and Integration of Heterogenous Information Technology Infrastructures in the Qatar Biobank.

Fthenou E, Al Emadi A, Mahal FF, Chettupuzhakaran LT, Al Thani A, Afifi N.

Biopreserv Biobank. 2019 Dec;17(6):494-505. doi: 10.1089/bio.2019.0067.

PMID:
31833809
4.

Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.

Holtzman NG, El Chaer F, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A.

Br J Haematol. 2019 Dec 5. doi: 10.1111/bjh.16261. [Epub ahead of print]

PMID:
31804722
5.

Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemia.

Crist M, Emadi A, Duffy A.

J Oncol Pharm Pract. 2019 Oct 21:1078155219881680. doi: 10.1177/1078155219881680. [Epub ahead of print]

PMID:
31635546
6.

A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.

Pratz KW, Rudek MA, Smith BD, Karp J, Gojo I, Dezern A, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Rosner G, Zahurak M, Wright JJ, Emadi A, Levis M; ETCTN-8922 study team.

Biol Blood Marrow Transplant. 2020 Feb;26(2):300-306. doi: 10.1016/j.bbmt.2019.09.023. Epub 2019 Sep 21.

PMID:
31550496
7.

Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics.

Lee MH, Lapidus RG, Ferraris D, Emadi A.

Molecules. 2019 Aug 28;24(17). pii: E3121. doi: 10.3390/molecules24173121. Review.

8.

Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.

Duong VH, Holtzman NG, Koka R, Singh ZN, Zou Y, Emadi A, Rapoport AP, Kocoglu MH, Baer MR, Badros AZ.

Leuk Lymphoma. 2019 Dec;60(14):3577-3580. doi: 10.1080/10428194.2019.1633639. Epub 2019 Jul 8. No abstract available.

PMID:
31282234
9.

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.

Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, Ruehle K, Kocoglu MH, Badros A, Hardy N, Yared J, Rapoport AP, Fontaine M, Emadi A, El Chaer F, Dahiya S.

Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7. No abstract available.

PMID:
31120638
10.

Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.

Adige S, Lapidus RG, Carter-Cooper BA, Duffy A, Patzke C, Law JY, Baer MR, Ambulos NP, Zou Y, Bentzen SM, Emadi A.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1105-1112. doi: 10.1007/s00280-019-03825-2. Epub 2019 Apr 9.

PMID:
30968179
11.

Gdn 3+@CNTs-PEG versus Gadovist®: In Vitro Assay.

Mehri-Kakavand G, Hasanzadeh H, Jahanbakhsh R, Abdollahi M, Nasr R, Bitarafan-Rajabi A, Jadidi M, Darbandi-Azar A, Emadi A.

Oman Med J. 2019 Mar;34(2):147-155. doi: 10.5001/omj.2019.27.

12.

Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.

Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Law JY, Lee ST, Sausville EA, Zimrin AB, Duffy AP, Lawson J, Emadi A.

J Oncol Pharm Pract. 2020 Jan;26(1):74-92. doi: 10.1177/1078155219838316. Epub 2019 Mar 27.

PMID:
30917738
13.

Advanced Micro- and Nano-Gas Sensor Technology: A Review.

Nazemi H, Joseph A, Park J, Emadi A.

Sensors (Basel). 2019 Mar 14;19(6). pii: E1285. doi: 10.3390/s19061285. Review.

14.

Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.

El Chaer F, Holtzman NG, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Hardy NM, Emadi A.

Acta Haematol. 2019;141(2):107-110. doi: 10.1159/000495558. Epub 2019 Jan 29.

PMID:
30695783
15.

Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.

El Chaer F, Ali OM, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Wong J, Yared JA, Griffiths EA, Emadi A.

Am J Hematol. 2019 Jan;94(1):E7-E8. doi: 10.1002/ajh.25317. Epub 2018 Nov 25. No abstract available.

16.

High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen.

Singh ZN, Duong VH, Koka R, Zou Y, Sawhney S, Tang L, Baer MR, Ambulos N, El Chaer F, Emadi A.

J Hematop. 2018 Sep;11(3):67-74. doi: 10.1007/s12308-018-0329-z. Epub 2018 Aug 9.

17.

Dietary Inflammatory Index and Site-Specific Cancer Risk: A Systematic Review and Dose-Response  Meta-Analysis.

Jayedi A, Emadi A, Shab-Bidar S.

Adv Nutr. 2018 Jul 1;9(4):388-403. doi: 10.1093/advances/nmy015.

18.
19.

Radiation Protection Knowledge, Attitude, and Practice (KAP) in Interventional Radiology.

Shabani F, Hasanzadeh H, Emadi A, Mirmohammadkhani M, Bitarafan-Rajabi A, Abedelahi A, Bokharaeian M, Masoumi H, Seifi D, Khani T, Sanchooli M, Moshfegh S, Ziari A.

Oman Med J. 2018 Mar;33(2):141-147. doi: 10.5001/omj.2018.26.

20.

Induction of Apoptosis and Inhibition of Invasion in Gastric Cancer Cells by Titanium Dioxide Nanoparticles.

Nasr R, Hasanzadeh H, Khaleghian A, Moshtaghian A, Emadi A, Moshfegh S.

Oman Med J. 2018 Mar;33(2):111-117. doi: 10.5001/omj.2018.22.

21.

Promyelocytic sarcoma of the right humerus: an unusual clinical presentation with unique diagnostic and treatment considerations.

Sawhney S, Holtzman NG, Davis DL, Kaizer H, Giffi V, Emadi A, Koka R.

Clin Case Rep. 2017 Sep 29;5(11):1874-1877. doi: 10.1002/ccr3.1212. eCollection 2017 Nov.

22.

Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.

Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh Z, Bentzen SM.

Cancer Chemother Pharmacol. 2018 Jan;81(1):217-222. doi: 10.1007/s00280-017-3459-6. Epub 2017 Nov 8.

PMID:
29119293
23.

Breaking Mitochondrial Fasting for Cancer Treatment: Old Wine in New Bottles.

Emadi A, Lapidus RG.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx069. No abstract available.

PMID:
29059434
24.

Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL.

El Chaer F, Holtzman N, Binder E, Porter NC, Singh ZN, Koka M, Rapoport AP, Emadi A.

Bone Marrow Transplant. 2017 Nov;52(11):1583-1584. doi: 10.1038/bmt.2017.191. Epub 2017 Sep 11. No abstract available.

PMID:
28892087
25.
26.

Inappropriate Packed RBC Transfusion in a Tertiary Care Center.

Sadeghi A, Belali S, Ali Asgari A, Morovat Z, Malekzadeh R, Emadi A.

Arch Iran Med. 2017 Feb;20(2):83-85. doi: 0172002/AIM.004.

27.

Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells.

Carter-Cooper BA, Fletcher S, Ferraris D, Choi EY, Kronfli D, Dash S, Truong P, Sausville EA, Lapidus RG, Emadi A.

Bioorg Med Chem Lett. 2017 Jan 1;27(1):6-10. doi: 10.1016/j.bmcl.2016.11.045. Epub 2016 Nov 17.

28.

Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.

Alshemmari SH, Rajan R, Emadi A.

Med Princ Pract. 2016;25(6):501-509. Epub 2016 Sep 21. Review.

29.

An Air-Coupled Multiple Moving Membrane Micromachined Ultrasonic Transducer With Inverse Biasing Functionality.

Emadi A, Buchanan DA.

IEEE Trans Ultrason Ferroelectr Freq Control. 2016 Aug;63(8):1140-7. doi: 10.1109/TUFFC.2016.2574336. Epub 2016 May 30.

PMID:
27254861
30.

Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.

Emadi A, Bade NA, Stevenson B, Singh Z.

Pharmaceuticals (Basel). 2016 Mar 10;9(1). pii: E12. doi: 10.3390/ph9010012.

31.

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.

Babakoohi S, Lapidus RG, Faramand R, Sausville EA, Emadi A.

Appl Immunohistochem Mol Morphol. 2017 May/Jun;25(5):334-337. doi: 10.1097/PAI.0000000000000342. Review.

PMID:
26945443
32.

Dr. Amir Masoud Emadi.

Emadi A, Malekzadeh R.

Arch Iran Med. 2016 Feb;19(2):163. doi: 0161902/AIM.0017. No abstract available.

33.

A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone.

Pidugu LS, Mbimba JC, Ahmad M, Pozharski E, Sausville EA, Emadi A, Toth EA.

BMC Struct Biol. 2016 Jan 28;16:1. doi: 10.1186/s12900-016-0052-x.

34.

Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.

Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Pidugu LS, Jaiswal A, Toth EA, Rassool FV, Etemadi A, Sausville EA, Baer MR, Emadi A.

Pharmaceuticals (Basel). 2016 Jan 19;9(1). pii: E4. doi: 10.3390/ph9010004.

35.

The role of β-elimination for the clinical activity of hypomethylating agents and cyclophosphamide analogues.

Reddy H, Duffy A, Holtzman NG, Emadi A.

Am J Cancer Ther Pharmacol. 2016;3(1):1-8. Epub 2016 Sep 19.

36.

Reverse Pseudohyperkalemia: An Important Clinical Entity in Chronic Lymphocytic Leukemia.

Mansoor S, Holtzman NG, Emadi A.

Case Rep Hematol. 2015;2015:930379. doi: 10.1155/2015/930379. Epub 2015 Sep 27.

37.

Exploiting AML vulnerability: glutamine dependency.

Emadi A.

Blood. 2015 Sep 10;126(11):1269-70. doi: 10.1182/blood-2015-07-659508. No abstract available.

PMID:
26359432
38.

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.

Fathi AT, Wander SA, Faramand R, Emadi A.

Semin Hematol. 2015 Jul;52(3):165-71. doi: 10.1053/j.seminhematol.2015.03.002. Epub 2015 Mar 17. Review.

PMID:
26111463
39.

Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.

Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG.

Leuk Res. 2015 Jul;39(7):719-29. doi: 10.1016/j.leukres.2015.04.002. Epub 2015 Apr 30.

PMID:
25982179
40.

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.

Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA.

Am J Hematol. 2015 May;90(5):E77-9. doi: 10.1002/ajh.23965. Epub 2015 Feb 27.

41.

Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study.

Etemadi A, Kamangar F, Islami F, Poustchi H, Pourshams A, Brennan P, Boffetta P, Malekzadeh R, Dawsey SM, Abnet CC, Emadi A.

BMC Med. 2015 Jan 15;13:8. doi: 10.1186/s12916-014-0237-8.

42.

Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis.

Bhatnagar V, Adelakun A, Kendall T, Holtzman N, Farshidpour M, Stevenson B, Chen Q, Emadi A.

Arch Iran Med. 2015 Jan;18(1):65-8. doi: 0151801/AIM.0015.

43.

High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.

Gourdin TS, Zou Y, Ning Y, Emadi A, Duong VH, Tidwell ML, Chen C, Rassool FV, Baer MR.

Cancer Genet. 2014 Oct-Dec;207(10-12):467-73. doi: 10.1016/j.cancergen.2014.09.001. Epub 2014 Sep 16.

PMID:
25441683
44.

Autophagy modulation: a target for cancer treatment development.

Duffy A, Le J, Sausville E, Emadi A.

Cancer Chemother Pharmacol. 2015 Mar;75(3):439-47. doi: 10.1007/s00280-014-2637-z. Epub 2014 Nov 25. Review.

PMID:
25422156
45.

Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation.

Oliver N, Short B, Thein M, Duong VH, Tidwell ML, Sausville EA, Baer MR, Kamangar F, Emadi A.

Leuk Lymphoma. 2015 Jul;56(7):2082-6. doi: 10.3109/10428194.2014.982640. Epub 2015 Jan 14.

PMID:
25379622
46.

Photoclinic.

Nathenson MJ, Emadi A.

Arch Iran Med. 2014 Nov;17(11):789-90. doi: 0141711/AIM.0016. No abstract available.

47.

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Sammons SL, Pratz KW, Smith BD, Karp JE, Emadi A.

Am J Hematol. 2014 Sep;89(9):936-8. doi: 10.1002/ajh.23782. Epub 2014 Jun 23. No abstract available.

48.

The state of the union on treatment of acute myeloid leukemia.

Emadi A, Karp JE.

Leuk Lymphoma. 2014 Nov;55(11):2423-5. doi: 10.3109/10428194.2014.897705. Epub 2014 Mar 25. No abstract available.

PMID:
24576164
49.

Asparaginase in the treatment of non-ALL hematologic malignancies.

Emadi A, Zokaee H, Sausville EA.

Cancer Chemother Pharmacol. 2014 May;73(5):875-83. doi: 10.1007/s00280-014-2402-3. Epub 2014 Feb 11. Review.

PMID:
24515335
50.

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV.

Exp Hematol. 2014 Apr;42(4):247-51. doi: 10.1016/j.exphem.2013.12.001. Epub 2013 Dec 11.

PMID:
24333121

Supplemental Content

Support Center